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ABSTRACT 
 
 
Background: After the publication of the CONSORT 2010 statement, no studies have 
been conducted to assess the reporting quality of randomized clinical trials (RCTs) 
regarding the impact of Photodynamic (PDT) or Laser diode therapy (LR) therapy in 
periodontitis. 
Objective:  To investigate the reporting quality of relevant RCTs in Pub Med during the 
period 1.1.2013-30.6.2018. 
Materials and methods: 18 relevant RCTs were selected among 191. Eligible RCTs 
included patients with chronic periodontitis randomly assigned to at least 2 therapies, one 
of which was PDT or LR therapy either primarily or adjunctively. Articles not written in 
English, involving animals or open flap (surgical) therapy or split mouth (SM) design or 
focusing only on microbiological and/or biochemical parameters, in vitro studies and study 
protocols were excluded. Reporting quality assessment was conducted using a modified 
CONSORT 2010 item checklist. Articles were separated into those published in journals 
endorsing the CONSORT (C) statement and those that are not (NC).  
Results: A mean CONSORT Compliance score (CCS) of 54.8% (46.9, 62.6%), 
(S.D=15.8) was calculated for the selected RCTs. Statistically significant difference was 
found between the percentages of C and NC articles achieving more than 65% CCS: 
RR=25, (1.8, 346.7). Νο significant differences between 2 groups in the number of items 
per each section (Title-Abstract, Introduction, etc.) reported by the 75% of the articles in 
each group was found. ‘Dental’ journals achieved a significantly higher CCS than  
‘General scientific’ journals.  [Mean Difference, MD = 18.4% (5.89, 30.91%)]. No 
differences were found across RCTs originating from different continents or published 
every year.  
Limitations: The amount of the available RCTs was limited. Assessment was conducted 
by a single investigator.  
Conclusions: The reporting quality of the RCTs for photodynamic or laser diode therapy 
in periodontitis is suboptimal. CONSORT articles achieved better Compliance scores than 
NO CONSORT. Further RCT reporting enhancement will advance both clinical research 
and every-day practice.  
 
Keywords: RCT, Reporting Quality Assessment, Periodontitis, Photodynamic therapy, Laser, CONSORT 
E-mail: natkar93@hotmail.com 
 
 
ΠΕΡΙΛΗΨΗ 
 
Εισαγωγή: Μετά από την δημοσίευση της δήλωσης CONSORT 2010 δεν υπάρχουν 
μελέτες που να αξιολογούν την ποιότητα καταγραφής των Τυχαιοποιημένων Κλινικών 
Δοκιμών (ΤΚΔ) για την Φωτοδυναμική (ΦΔΘ) ή την θεραπεία με Διοδικό Laser (ΔΛ) και 
την επίδρασή της στις κλινικές παραμέτρους της περιοδοντίτιδας. 
Σκοπός: H διερεύνηση της ποιότητας αναφοράς των σχετικών ΤΚΔ που ανευρέθηκαν 
στο PubMed κατά την χρονική περίοδο 1.1.2013-30.6.2018. 
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Μέθοδοι: Επιλέχθηκαν 18 ΤΚΔ από συνολικά 191 μελέτες. Προϋποθέσεις επιλογής ήταν 
οι ΤΚΔ να είναι γραμμένες στην αγγλική γλώσσα και να περιλαμβάνουν ασθενείς με 
χρόνια περιοδοντίτιδα οι οποίοι τυχαία χωρίστηκαν σε δύο ομάδες τουλάχιστον, σε μία εκ 
των οποίων εφαρμόστηκε θεραπευτικά ΦΔΘ ή ΔΛ (κύρια ή επικουρικά).  Δεν 
συμπεριλήφθηκαν μελέτες σε ζώα ή ‘Ιn vitro’, θεραπευτικά πρωτόκολλα, καθώς και ΤΚΔ 
με σχεδιασμό Split Mouth, (SM) ή που αφορούσαν χειρουργική αντιμετώπιση της 
περιοδοντίτιδας ή που επικεντρώνονταν αποκλειστικά στις μικροβιολογικές ή και 
βιοχημικές παραμέτρους της νόσου. Η αξιολόγηση των ΤΚΔ έγινε με την χρήση 
τροποποιημένης λίστας στοιχείων CONSORT 2010. Οι μελέτες χωρίστηκαν σε αυτές που 
δημοσιεύτηκαν σε περιοδικά που στηρίζουν την δήλωση CONSORT (C) και σε αυτά που 
δεν την στηρίζουν (NC) και πραγματοποιήθηκαν συγκρίσεις μεταξύ τους. 
Αποτελέσματα: O μέσος όρος της βαθμολογίας (CCS) που συγκέντρωσαν οι 
συμπεριληφθείσες ΤΚΔ ήταν 54.8% (46.9, 62.6%), (Τ.Α=15.8). Στατιστικά σημαντική 
διαφορά βρέθηκε μεταξύ των ποσοστών των C και NC άρθρων που συγκέντρωσαν CCS 
μεγαλύτερο από 65%: RR=25, (1.8, 346.7). Δεν υπήρχαν σημαντικές διαφορές μεταξύ 
των δύο ομάδων στον αριθμό των στοιχείων της λίστας ανά τμήμα άρθρου (Τίτλος-
Απόσπασμα, Εισαγωγή, κλπ.) που αναφέρθηκαν από το 75% των εργασιών κάθε 
ομάδας. Tα ‘Οδοντιατρικά’ περιοδικά συγκέντρωσαν στατιστικά σημαντικά μεγαλύτερο 
CCS σχετικά με τα άλλα ‘Γενικού επιστημονικού ενδιαφέροντος’ περιοδικά: [Διαφορά 
Μέσου Όρου, Δ.Μ.Ο. = 18.4% (5.89, 30.91%)]. Δεν ανευρέθηκαν διαφορές ανάμεσα στις 
ΤΚΔ που προέρχονταν από διαφορετικές ηπείρους ή που δημοσιεύτηκαν την κάθε 
χρονιά, όσον αφορά το CCS. 
Περιορισμοί: Ο αριθμός των διαθέσιμων ΤΚΔ ήταν περιορισμένος. Η αξιολόγηση 
πραγματοποιήθηκε από έναν ερευνητή.  
Συμπεράσματα: Η ποιότητα καταγραφής των μελετών για την ΦΔΘ/ΔΛ θεραπεία στην 
περιοδοντίτιδα είναι χαμηλή. Τα C άρθρα πέτυχαν καλύτερο CCS σε σχέση με τα NC. 
Περαιτέρω βελτίωση της ποιότητας αναφοράς των ΤΚΔ θα προάγει την κλινική έρευνα 
και πρακτική. 
 
Λέξεις-Κλειδιά: Τυχαιοποιημένη κλινική μελέτη, Αξιολόγηση ποιότητας καταγραφής, Περιοδοντίτιδα, 
Φωτοδυναμική θεραπεία, Laser, CONSORT 
Ηλεκτρονική διεύθυνση: natkar93@hotmail.com 
 
 
 
INTRODUCTION 
 
A right clinical decision can be reached by having access to reliable meta-
analyses, as well as to carefully planned, well-conducted and free of bias clinical trials. 
Proper clinical trial selection is also a prerequisite for definitive meta-analyses.  RCT is a 
study design that randomly assigns participants into an experimental group or to a control 
group (Himmeralb Health Sciences Library, 2011).  It is considered to be the ideal type of 
clinical research to examine the effectiveness of treatment interventions in health 
sciences (Higgins et al, 2011) by ensuring that treatment and control groups are 
comparable in respect of prognosis and responsiveness to treatment (Kleijnen J et al in: 
Maynard A, 1997) and thus preventing bias. Evidence-based hierarchies place RCTs just 
below systematic reviews as the highest form of evidence (Concato et al. 2000; Turner et 
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al. 2012; Fleming et al. 2012). Nevertheless, there are indications in the bibliography that 
the quality of many RCTs is inadequate. (Ravindranath et al, 2006, Rios et al, 2008, 
Turner et al, 2012). 
Thorough and accurate reporting advances RCTs’ evaluation (Williams 2010) and 
enables their reproducibility. Compliance with a framework of certain recommendations, 
formulated by common consent and expected to be strictly reported in scientific journals, 
is considered to enhance the quality of RCT reporting (Der Simonian et al, 1982).   The 
CONSORT statement is an evidence-based, minimum set of guidelines for reporting 
randomized trials. It offers a standard way for authors to prepare reports of trial findings, 
facilitating their complete and transparent reporting, and aiding their critical appraisal and 
interpretation (http://www.consort-statement.org/). It was originally published in 1996 
(Begg et al.) and has been revised twice since then (Moher et al. 2001, Schulz et al. 
2010). It is currently endorsed by several prominent editorial organizations including the 
International Committee of Medical Journal Editors (ICMJE) and the World Association of 
Medical Editors (WAME).      (http://www.consort-statement.org/about-consort/impact-of-
consort). There is evidence that it is associated with an upgrade in the RCT reporting 
quality (Hopewell et al, 2010, Egger et al, 2001, Plint et al, 2006).  
A number of publications have studied the quality of reports of RCTs in dentistry 
(Cioffi et al 2011, Saltaji et al, 2017, Pandis et al 2010) and in its subspecialties: in 
Periodontology (Leow et al, 2016), in Pediatric dentistry (Al-Namankany et al, 2009, 
Rajasekharan et al, 2014), in Implantology (Cairo et al, 2012, Tonetti et al, 2012), in 
Orthodontics (Koletsi et al, 2016, Pandis et al, 2014, Kloukos et al, 2015, Lempesi 2014), 
in Prosthodontics (Patel et al, 2014, Kloukos et al, 2015) and in Endodontics (Lucena et 
al, 2017). As far as we know, there has been no review of the quality of reporting of RCTs 
for PDT or LR therapy in Periodontitis. A relative study concerned the reporting quality 
assessment of RCT abstracts published in leading laser medicine journals using the 
CONSORT for abstracts guidelines (Lu Jin et al, 2016). 
In the present study, the quality of reporting of RCTs for PDT or LR therapy in 
patients with periodontitis has been assessed using the items of the expanded 
CONSORT 2010 checklist. The period covered is from 2013 to first semester of 2018. 
 
 
 
MATERIALS AND METHODS 
 
Eligibility criteria 
 
Inclusion criteria were clinical trials that had allocated patients to at least two 
treatment groups (test and control) randomly. Participants with different types of 
periodontitis were included: chronic, aggressive, moderate, severe generalized, with 
class II furcation or residual pockets in maintenance. PDT or LR therapy was 
implemented either primarily or adjunctively to the test group for the nonsurgical treatment 
of periodontitis while Scaling and Root Planing (SRP) was applied to the control group. 
Only studies reporting the effect on the reduction of probing depth (PD) or the Clinical 
Attachment Level (CAL) as one of the outcomes, were included. There was no minimum 
length of follow-up.  
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Exclusion criteria were: systematic reviews, meta-analyses, protocol studies, case series, 
in vitro studies and studies involving open flap therapy or focusing exclusively on the 
microbiological and/or biochemical results of PDT or LR therapy. Split-mouth design 
RCTs were not included because they required a different assessment tool, the 
CONSORT 2010 extension checklist for reporting within person randomized trials (Pandis 
et al, 2017) 
 
Data sources and searching strategy 
 
PubMed was searched for studies written in English and published between 
1.1.2013 and 30.6.2018, by implementing ‘Advanced Search’. The last search was run 
on 2 August 2018. The following search terms were used:  
 
(((random OR at random OR randomly OR randomized OR randomization OR RCT OR 
randomized clinical trial OR randomized controlled trial OR controlled clinical trial OR 
random allocation OR double blind method OR single blind method)) AND (laser diode 
OR laser therapy OR photodynamic therapy OR laser)) AND (periodontitis OR periodontal 
therapy OR periodontal disease ΟR periodontal treatment). 
 
The limiter ‘humans’ was used. 
 
 
 
Data extraction 
 
Information was extracted from each article regarding: Journal published, its 
content (dental or general scientific) and CONSORT endorsement or not, year of 
publication, region of authorship, number of centers involved, number of groups to which 
interventions were allocated, type of therapy applied to the test group (PDT or LR), 
participants’ characteristics, sample size and statistical methods used.  
No authors were contacted in cases of inaccuracies or unclear results. 
 
 
Assessment procedure 
 
The CONSORT 2010 checklist (http://www.consort-statement.org) was expanded 
and used for the assessment of the RCTs. Compound questions in the original checklist 
were split into simple ones for the purpose of accuracy and they were scored separately 
(Table 1). Certain criteria in the original CONSORT 2010 checklist did not apply for any 
of the selected studies. Therefore they were omitted. Those criteria were: 3b [Important 
changes to methods after trial commencement (such as eligibility criteria), with reasons], 
6b (Any changes to trial outcomes after the trial commenced, with reasons), 7b (When 
applicable, explanation of any interim analyses and stopping guidelines) and 14b (Why 
the trial ended or was stopped). 
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In accordance with the CONSORT authors’ recommendations (Moher et al, 2010), 
additional criteria were included: In ‘Abstract’, the items from the ‘CONSORT for 
Abstracts’ (Hopewell et al, 2008) checklist –apart from ‘Trial status’-, in ‘Materials and  
Methods’ (particularly in the ‘Statistical methods’), item Nr 47: ‘Details of the statistical 
analysis (such as ITT analysis)’, in ‘Results’, item Nr 49: ‘Participant flow diagram’ and in 
‘Discussion’, items Nr 65-67: ‘Comparison with relevant findings from other published 
studies’, ‘Consideration of possible mechanisms and explanation’ and ‘Clinical and 
research implications’ (as suggested also by ‘Annals of Internal Medicine’). 
All items were scored as ‘1’ when reported or ‘0’ when not reported. Non-applicable 
items did not receive any score. When an item was reported in a section of the trial 
different from which it was expected (i.e.: in ‘Results’ instead of ‘Methods’), then it was 
considered as not reported. Items from ‘Other information’ section (Nr 70: ‘Registration, 
Nr 71: ‘Protocol’ and Nr 72: ‘Funding’) as well as Item 55: ‘Dates defining the periods of 
recruitment and follow-up’, were considered as positive if they were reported, 
independently from the section in which they were mentioned. 
When the primary outcome was unclear, it was concluded by the sample size 
calculation (Moher et al, 2001). In case of improper statistical methods or unclear results, 
items 2, 17, 19, 59, 60 and 64-69 received a negative response. If certain items from the 
‘Results’ section were not directly reported, they were extracted from the tables and 
figures wherever possible.  
The ‘CONSORT explanation and elaboration document’ (Moher et al, 2010) was 
used as guideline. The evaluation regarded the reporting of the selected criteria, not the 
verification of their implementation.  
The scores for the 72 items were combined and a percentage score was calculated 
for each trial (CONSORT Compliance score-CCS).   
 
 
Statistical analysis 
 
Trials were separated into 2 categories (http://www.consort-statement.org/about-
consort/endorsers1) according to whether the journal they were published in is endorsing 
the CONSORT 2010 statement (8/18, 44.4%) or not (10/18, 54.6%). Reported items were 
also divided into 6 sections: Title-Abstract, Introduction, Materials and Methods, Results, 
Discussion and Other information. Descriptive statistics and percentage compliance by 
modified CONSORT checklist item were reported for all published trials and for each of 
the two groups, C and NC, separately. The percentage of articles that reported at least 
65% of the checklist items was calculated and comparisons between 2 groups were made 
applying Fisher’s exact test. The numbers of items per each section that were reported 
by 75% and more of the RCTs of the C group were compared with the corresponding of 
the NC groups using Fisher’s Exact Test and Pearson’s Chi Square.  
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Table 1: Self-designed checklist for assessing the quality of reporting of RCTs based on the CONSORT 2010 checklist, 
frequency distribution of the included items in total and by CONSORT / no CONSORT endorsement journal. Note that 
some items are not applicable to all RCTs. 
Nr Section Modified CONSORT item 
Nr of RCTs 
to which 
the item 
is 
applicable 
(%)  
Compliance Nr of RCTs 
to which 
the item 
is 
applicable 
(%) 
Compliance Nr of RCTs 
to which 
the item 
is 
applicable 
(%) 
Compliance 
TOTAL CONSORT 
No 
CONSORT 
N (%) N (%) N (%) 
1 
Title Identification as a randomized trial in the title 18 (100) 11 (61.1) 7 (100) 7 (100) 11 (100) 4 (36.4) 
2 Abstract Structured summary of trial design, methods, 
results and conclusions  
18 (100) 12 (66.7) 7 (100) 6 (85.7) 11 (100) 6 (54.5) 
3  Contact details of the corresponding author 18 (100) 14 (77.8) 7 (100) 3 (42.9) 11 (100) 11 (100) 
4  Description or trial design 18 (100) 14 (77.8) 7 (100) 7 (100) 11 (100) 7 (63.6) 
5  Eligibility criteria for participants 18 (100) 0 (0) 7 (100) 0 (0) 11 (100) 0 (0) 
6  Settings where the data were collected 18 (100) 1 (5.6) 7 (100) 0 (0) 11 (100) 1 (9.1) 
7  Interventions intended for each group 18 (100) 18 (100) 7 (100) 7 (100) 11 (100) 11 (100) 
8 
 
Specific objectives or hypotheses for this 
report 
18 (100) 17 (94.4) 7 (100) 7 (100) 11 (100) 10 (90.9) 
9  Clearly defined primary outcome for this report 18 (100) 4 (22.2) 7 (100) 3 (42.9) 11 (100) 1 (9.1) 
10 
 
How participants were allocated to 
interventions 
18 (100) 2 (11.1) 7 (100) 1 (14.3) 11 (100) 1 (9.1) 
11 
 
Whether participants were blinded to group 
assignment 
18 (100) 2 (11.1) 7 (100) 1 (14.3) 11 (100) 1 (9.1) 
12  Care givers were blinded to group assignment 18 (100) 1 (5.6) 7 (100) 1 (14.3) 11 (100) 0 (0) 
13 
 
Those assessing the outcomes were blinded 
to group assignment 
18 (100) 2 (11.1) 7 (100) 2 (28.6) 11 (100) 0 (0) 
14 
 
Number of participants randomized to each 
group 
18 (100) 13 (72.2) 7 (100) 5 (71.4) 11 (100) 10 (90.9) 
15  Number of participants analyzed in each group 18 (100) 4 (22.2) 7 (100) 1 (14.3) 11 (100) 3 (27.3) 
16 
 
 For the primary outcome a result for each 
group 
18 (100) 2 (11.1) 7 (100) 1 (14.3) 11 (100) 1 (9.1) 
17  The estimated effect size and its precision 18 (100) 3 (16.7) 7 (100) 2 (28.6) 11 (100) 1 (9.1) 
18  Important adverse events or side effects 18 (100) 0 (0) 7 (100) 0 (0) 11 (100) 0 (0) 
19  General interpretation of the results 18 (100) 12 (66.7) 7 (100) 5 (71.4) 11 (100) 7 (63.6) 
20  Registration number and name of trial registry 18 (100) 2 (11.1) 7 (100) 2 (28.6) 11 (100) 0 (0) 
21  Source of funding 18 (100) 5 (27.8) 7 (100) 5 (71.4) 11 (100) 0 (0) 
22 Introduction Scientific background  18 (100) 16 (88.9) 7 (100) 7 (100) 11 (100) 9 (81.8) 
23 Explanation of rationale 18 (100) 16 (88.9) 7 (100) 7 (100) 11 (100) 9 (81.8) 
24  Specific objectives or hypotheses 18 (100) 16 (88.9) 7 (100) 7 (100) 11 (100) 9 (81.8) 
25 Materials 
and 
methods 
Description of trial design (such as parallel, 
factorial) 
18 (100) 15 (83.3) 7 (100) 6 (85.7) 11 (100) 9 (81.8) 
26 Allocation ratio 18 (100) 13 (72) 7 (100) 4 (57.1) 11 (100) 9 (81.8) 
27 Eligibility criteria for participants 18 (100) 18 (100) 7 (100) 7 (100) 11 (100) 11 (100) 
28  Settings where the data were collected 18 (100) 16 (88.9) 7 (100) 6 (85.7) 11 (100) 10 (90.9) 
29  Locations where the data were collected 18 (100) 15 (83.3) 7 (100) 6 (85.7) 11 (100) 9 (81.8) 
30 
 
The interventions for each group with 
sufficient details to allow replication 
18 (100) 17 (94.4) 7 (100) 7 (100) 11 (100) 10 (90.9) 
31  How and when they were actually administered 18 (100) 16 (88.9) 7 (100) 7 (100) 11 (100) 9 (81.8) 
32 
 
Completely defined pre-specified primary and 
secondary outcome measures 
18 (100) 14 (77.8) 7 (100) 6 (85.7) 11 (100) 8 (72.7) 
33 
 
How primary and secondary outcome 
measures were assessed 
18 (100) 17 (94.4) 7 (100) 7 (100) 11 (100) 10 (90.9) 
34 
 
When primary and secondary outcome 
measures were assessed 
18 (100) 18 (100) 7 (100) 7 (100) 11 (100) 11 (100) 
35  How sample size was determined 18 (100) 14 (77.8) 7 (100) 7 (100) 11 (100) 11 (100) 
36 
 
Method used to generate the random 
allocation sequence 
18 (100) 11 (61.1) 7 (100) 6 (85.7) 11 (100) 5 (45.5) 
37 
 
Type of randomization; Details of any restriction 
(such as blocking and block size) 
18 (100) 9 (50) 7 (100) 4 (57.1) 11 (100) 5 (45.5) 
38 
 
Mechanism used to implement the random 
allocation sequence (such as sequentially 
numbered containers) 
18 (100) 6 (33.3) 7 (100) 5 (71.4) 11 (100) 1 (9.1) 
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39 
 
Description of any steps taken to conceal the 
sequence until interventions were assigned 
18 (100) 8 (44.4) 7 (100) 5 (71.4) 11 (100) 3 (27.3) 
40 
 
Who generated the random allocation 
sequence  
18 (100) 5 (27.8) 7 (100) 3 (42.9) 11 (100) 2 (18.2) 
41  Who enrolled participants 18 (100) 3 (16.7) 7 (100) 3 (42.9) 11 (100) 0 (0) 
42  Who assigned participants to interventions 18 (100) 6 (33.3) 7 (100) 3 (42.9) 11 (100) 3 (27.3) 
43 
 
If done, who was blinded after assignment to 
interventions (for example, participants, care 
providers, those assessing outcomes) 
18 (100) 13 (72.2) 7 (100) 7 (100) 11 (100) 6 (54.5) 
44  How was blinding done 18 (100) 10 (55.6) 7 (100) 5 (71.4) 11 (100) 5 (45.5) 
45 
 
If relevant, description of the similarity of 
interventions 
18 (100) 4 (22.2) 7 (100) 2 (28.6) 11 (100) 2 (18.2) 
46 
 
Statistical methods used to compare groups 
for primary and secondary outcomes 
18 (100) 17 (94.4) 7 (100) 7 (100) 11 (100) 10 (90.9) 
47  ITT analysis 18 (100) 3 (16.7) 7 (100) 3 (42.9) 11 (100) 0 (0) 
48 
 
Methods for additional analyses, such as 
subgroup analyses and adjusted analyses 
18 (100) 3 (16.7) 7 (100) 1 (14.3) 11 (100) 2 (18.2) 
49 Results Flow diagram 18 (100) 10 (55.6) 7 (100) 7 (100) 11 (100) 3 (27.3) 
50 
 
For each group, the numbers of participants 
who were randomly assigned 
18 (100) 16 (88.9) 7 (100) 7 (100) 11 (100) 9 (81.8) 
51 
 
For each group, the numbers of participants 
who received intended treatment 
18 (100) 15 (83.3) 7 (100) 7 (100) 11 (100) 8 (72.7) 
52 
 
For each group, the numbers of participants 
who were analyzed for the primary outcome 
18 (100) 15 (83.3) 7 (100) 7 (100) 11 (100) 8 (72.7) 
53 
 
For each group, losses and exclusions after 
randomization 
18 (100) 16 (88.9) 7 (100) 7 (100) 11 (100) 9 (81.8) 
54 
 
Reasons for losses and exclusions after 
randomization 
10 (100) 9 (90) 5 (100) 5 (100) 5 (100) 4 (80) 
55 
 
Dates defining the periods of recruitment and 
follow-up 
18 (100) 12 (66.7) 7 (100) 6 (85.7) 11 (100) 6 (54.5) 
56 
 
A table showing baseline demographic and 
clinical characteristics for each group 
18 (100) 12 (66.7) 7 (100) 4 (57.1) 11 (100) 8 (72.7) 
57 
 
For each group, number of participants 
(denominator) included in each analysis and 
whether the analysis was by original assigned 
groups 
18 (100) 14 (77.8) 7 (100) 6 (85.7) 11 (100) 8 (72.7) 
58 
 
For each primary and secondary outcome, 
results for each group 
18 (100) 17 (94.4) 7 (100) 7 (100) 11 (100) 10 (90.9) 
59 
 
For each primary and secondary outcome the 
estimated effect size  
18 (100) 2 (11.1) 7 (100) 1 (14.3) 11 (100) 1 (9.1) 
60 
 
For each primary and secondary outcome, its 
precision (such as 95% confidence interval) 
18 (100) 0 (0) 7 (100) 0 (0) 11 (100) 0 (0) 
61 
 
For binary outcomes, presentation of both 
absolute and relative effect sizes is 
recommended 
12 (100) 0 (0) 5 (100) 0 (0) 7 (100) 0 (0) 
62 
 
Results of any other analyses performed, 
including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from 
exploratory 
18 (100) 8 (44.4) 7 (100) 2 (28.6) 11 (100) 6 (54.5) 
63 
 
All important harms or unintended effects in 
each group (for specific guidance see 
CONSORT for harms) 
18 (100) 11 (61.1) 7 (100) 5 (71.4) 11 (100) 6 (54.5) 
64 Discussion Trial limitations, addressing sources of 
potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
18 (100) 11 (61.1) 7 (100) 6 (85.7) 11 (100) 5 (45.5) 
65 
 
Comparison with relevant findings from other 
published studies 
18 (100) 12 (66.7) 7 (100) 6 (85.7) 11 (100) 6 (54.5) 
66 
 
Consideration of possible mechanisms and 
explanation 
18 (100) 9 (50) 7 (100) 4 (57.1) 11 (100) 5 (45.5) 
67  Clinical and research implications 18 (100) 8 (44.4) 7 (100) 4 (57.1) 11 (100) 4 (36.4) 
68 
 
Generalizability (external validity, applicability) 
of the trial findings 
18 (100) 5 (27.8) 7 (100) 4 (57.1) 11 (100) 1 (9.1) 
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69 
 
Interpretation consistent with results, 
balancing benefits and harms, and 
considering other relevant evidence 
18 (100) 11 (61.1) 7 (100) 7 (100) 11 (100) 4 (36.4) 
70 Other 
information 
Registration number and name of trial registry 18 (100) 6 (33.3) 7 (100) 5 (71.4) 11 (100) 1 (9.1) 
71 Where the full trial protocol can be accessed, 
if available 
18 (100) 11 (61.1) 7 (100) 4 (57.1) 11 (100) 7 (63.6) 
72 
  
Sources of funding and other support (such as 
supply of drugs), role of funders 
18 (100) 17 (94.4) 7 (100) 7 (100) 11 (100) 10 (90.9) 
 
No comparisons between articles published in journals with high and low impact 
factor (IF) were implemented. The particular journals addressed to different target groups 
and consequently, their IF depended also on each specialists’ group population. 
Therefore it could not be considered as a sufficient index of the importance of the journal. 
Instead, journals were divided to ‘Dental’ (8/18, 44.4%), being addressed to dentists 
exclusively and ‘General Scientific’ (of general scientific interest) (10/18, 55.6%), aimed 
also to other professionals, apart from dentists. Mean CCSs for RCTs in ‘Dental’ and 
‘General Scientific’ journals, as well as for studies being published each year or 
originating from different continents, were calculated and found to follow the normal 
distribution in all cases (Shapiro-Wilk normality test). Comparisons between groups were 
made using the Independent samples T-test (‘Dental’ and ‘General’ journals) and the One 
Way ANOVA (among studies published each year and also among articles originating 
from different continents).  
The percentages of the C and NC studies that reported each item of the checklist 
were compared by the use of Pearson’s Chi Square or Fisher’s exact test. 
All statistical analyses were made on the IBM SPSS v.21 package. Differences 
were considered statistically significant when p<0.05. 
 
Figure 1. Flow chart of the search strategy. 
    
191 studies reviewed by title   
     
   
  
153 excluded: 18 surgical, 27 implants, 9 
orthodontics, 13 endodontics, 23 systematic 
reviews and meta-analyses, 3 study protocols, 5 
‘in vitro’ studies, 1 case-series, 35 split mouth 
design (SM) and 19 irrelevant. 
   
 
     
38 studies reviewed by abstract   
     
     9 were excluded: 1 duplicate, 8 SM  
    3 not retrievable 
     
26 studies  reviewed by full text   
     
     8 excluded: 2 measured exclusively 
microbiological or biochemical indices, 6 SM     
     
18 were included   
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RESULTS 
 
191 studies were initially searched (See flow diagram Figure 1).  After title 
assessment, 153 articles were excluded: 18 involved surgical treatment of periodontitis, 
27 referred to implants, 22 to other dental specialties (9 to orthodontics and 13 to 
endodontics), 23 were systematic reviews and meta-analyses, 3 study protocols, 5 ‘in 
vitro’ studies, 1 case-series, 35 had a split mouth  (SM) design and 19 were irrelevant. 
Following the abstract evaluation of the 38 articles that remained, 9 were excluded 
(1 was a duplicate and 8 were SM) and 3 could not be retrieved. From the 26 studies that 
were full-text reviewed, 8 were excluded (2 measured exclusively microbiological or 
biochemical indices and 6 were SM). Finally 18 RCTs, involving 732 patients, were 
evaluated. A list of the included studies can be found in the Appendix. 
 
 
        Table 2: Characteristics of the RCTs studied 
   
No (%) of trials 
(n=18) 
 
Year of 
publication 
2013 1 (5.6) 
 2014 4 (22.2) 
 2015 4 (22.2) 
 2016 4 (22.2) 
 2017 4 (22.2) 
 2018 1 (5.6) 
    
 
Journal 
OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS 1 (5.6) 
 LASERS IN MEDICAL SCIENCE 5 (27.8) 
 PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY 2 (11.1) 
 OF CLINICAL PERIODONTOLOGY 5 (27.8) 
 OF PHOTOCHEMISTRY AND PHOTOBIOLOGY 1 (5.6) 
 INTERNATIONAL OF DENTAL HYGIENE 1 (5.6) 
 OF PERIODONTOLOGY 1 (5.6) 
 OF CLINICAL ORAL INVESTIGATION 1 (5.6) 
 QUINTESSENCE 1 (5.6) 
    
 CONSORT 
endorsement 
Yes 7 (38.9) 
 No 11 (61.1) 
    
 
Continent 
Europe 6 (33.3) 
 South America 5 (27.8) 
 Asia 7 (38.9) 
    
 Nr of authors <4 2 (11.1) 
  4, 5, 6 6 (33.3) 
  >6 10 (55.6) 
    
 Nr of centers Single 17 (94.4) 
  Multi 1 (5.6) 
    
 Type of therapy Photodynamic 12 (66.7) 
  Laser 6 (33.3) 
  Antibiotics 2 (11.1) 
    
 
Patients 
Smokers 1 (5.6) 
 Pre-diabetics, Diabetics 3 (16.7) 
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Trial characteristics 
 
The characteristics of the selected RCTs are shown in Table 2. The majority of the 
RCTs were published equally in the Journal of Clinical Periodontology (5/18, 27.8%) and 
in the Journal of Lasers in Medical Science followed by the Journal of Photodiagnosis 
and Photodynamic therapy (2/18, 11.1%). The total number of journals is 9. 3 of them -
corresponding to the 39% (7/18) of the articles- are endorsing the CONSORT Statement 
whereas the other 6 are not [61% (11/18) of the studies]. In fact all the C journals are 
‘Dental’, whereas none of the ‘General Scientific’ journals endorse the CONSORT 
statement. In total, the ‘Dental’ journals published the 44.4% (8/18) of the articles and the 
‘General Scientific’ the 55.6% (10/18) of them. 
The RCTs αre distributed equally among each year during the period 2014-2017: 
4/18 (22.2%). In 2013 there is only 1 article (5.6%) and the same applies for the first 
semester of 2018. Most of the studies originates from Asia (7/18, 38.9%), followed by 
Europe (6/18, 33.3%) and by South America (5/18, 27.8%). Over the half of them (10/18, 
55.6%) are written by more than 6 authors and the majority is single centered (17/18, 
94.4%). 
66.7% (12/18) implemented PDT therapy whereas 33.3% LR therapy. In 3 studies 
(16.7%) interventions were assigned to 3 groups and in 2 (11.1%) antibiotics were used 
adjunctively. Most of the studies involved no smokers (17/18, 94.6%) and patients with 
no systematic diseases (15/18). There are however a few (3/18, 16.7%) concerning 
diabetic (2, 11.1%) and pre-diabetic patients (1, 5.6%). 
 
 
Descriptives 
 
CONSORT Compliance Scores ranged from 27% to 77%. The average score was 
calculated 54.8% (46.9, 62.6%). 12/18 studies (66.7%) scored over 50%, 6/18 (33.3%) 
more than 65% and only 1/18 (5.6%) over 75%. Table 1 shows the number and the 
percentage of studies that reported each individual criterion.  
Τhe reported items that achieved 100% compliance score among RCTs were No 
7: ‘Interventions intended for each group’ (in Abstract),  Nr 27: ‘Eligibility criteria for 
participants’ and Nr 34: ‘When primary and secondary outcome measures were 
assessed’. Furthermore, items Nr 8: ‘Specific objectives or hypotheses for this report’ (in 
Abstract), Nr 30: ‘The interventions for each group with sufficient details to allow 
replication’, Nr 33: ‘How primary and secondary outcome measures were assessed’, Nr 
46: ‘Statistical methods used to compare groups for primary and secondary outcomes’, 
Nr 52: ‘For each group, the numbers of participants who were analyzed for the primary 
outcome’ and Nr 58: ‘For each primary and secondary outcome, results for each group’, 
Nr 72 ‘Sources of funding or other support’ were reported in 94% (17/18) of the studies. 
Item Nr 54: ‘Reasons for losses and exclusions after randomization’ was included in 11 
out of 12 RCTs in which it was applicable (91%). Following, criteria from Discussion:  Nr 
65: ‘Comparison with relevant findings from other published studies’, Nr 64: ‘Trial 
limitations, addressing sources of potential bias, imprecision, and if relevant, multiplicity 
of analyses’ and Nr 69: ‘Interpretation consistent with results, balancing benefits and 
harms and considering other relevant evidence’ were reported in 67% (12/18), 61% 
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(11/18) and 61% of the articles respectively. In fact, all the studies that implemented 
appropriate statistical analysis and formulated clear results, (100% -12/12) reported item 
65 and most of them (92% -11/12) referred to the items 64 and 69. 
On the contrary, the most underreported items were found in Abstract: Nr 5: 
‘Eligibility criteria for participants’ (0%), Nr 18: ‘Important adverse events or side effects’ 
(0%), Nr 6: ‘Settings where the data were collected’ (6%, 1/18) and Nr 12: ‘Care givers 
were blinded to group assignment’ (6%). Regarding the reporting of the results for each 
primary or secondary outcome, criterion Nr 59: ‘For each primary and secondary outcome 
the estimated effect size’ was reported in 2 of the 18 articles (11%), whereas none of the 
RCTs was referred to item Nr 61: ‘For binary outcomes, presentation of both absolute 
and relative effect sizes is recommended’ (where applicable) or to Nr 60 ‘For each primary 
and secondary outcome, its precision (such as 95% confidence interval)’. In 12/18 (67%) 
of the articles, p-values between groups were provided instead. 
Additionally, concerning statistical analysis, it was examined whether there was 
compliance with the CONSORT authors’ recommendation: ‘Treating multiple 
observations from one participant as independent data is a serious error; (Altman et al, 
1997, Bolton, 1998) … Data analysis should be based on counting each participant once 
or should be done by using more complex statistical procedures’ (Greenland 2000). 
Taking into consideration that periodontitis examination involves multiple measurements 
in each patient, it was found that only 7 out of 18 RCTs (38.9%) reported that a patient 
level analysis for each of the clinical parameters had been implemented. 
Moreover, 6 studies in total, with improper statistical analysis or unclear results 
were identified:  2 of them (11%) applied inappropriate statistical methods (Paired-Sample 
t-test for intergroup differences), 2 (11%) implemented no comparisons between groups, 
1 (6%) provided no p-values or CIs -only boxplots- and in 1 (6%) it was not obvious 
whether p-values referred to intergroup or intragroup differences. Their mean CCS was 
38.67% while the mean CCS of the rest articles increased to 62.83%. The former studies 
had the following characteristics: 66.7% (4/6) originated from Asia and 33.3% (2/6) from 
Europe, 83.3% (5/6) were published in NC journals and in ‘General Scientific’ journals. 
Regarding Randomization, only 61.1% of the studies reported the ‘Method used to 
generate the random allocation sequence’ (Nr 36) and 50% the ‘Type of randomization’ 
(Nr 37), even though they were characterized as randomized. The reporting of the 
development and implementation of the allocation concealment represented by items Nr 
38 (Mechanism), 39 (Concealment of the sequence until assignment of interventions), 40 
(Allocation sequence generation), 41 (Participant enrollment) and 42 (participant 
assignment to interventions) was inadequate: The corresponding reporting percentages 
were: 33.3%, 44.4%, 27.8%, 16.7% and 33.3%. Finally, blinding was better reported than 
allocation concealment but still sub optimally: 27.8% of the studies did not refer who was 
blinded after intervention assignment (Nr 43) and 44.4% how was blinding done (Nr 44). 
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Comparisons 
 
The average CCS for the C articles was calculated 65.7% (±7.2) and for the NC 
47.8% (±9). 6/7 (85.7%) studies of the C group scored above 50% whereas 6/11 (54.5%) 
in the NC group achieved this score. Only 
1 article (belonging to the C group) was 
evaluated with a CCS more than 75%. 
The RCTs that covered more than 65% of 
the modified CONSORT items were: C 
journals: 5/7 (71.4%), NC: 1/11 (9.1%), 
expressing a statistically significant 
difference in compliance with CONSORT 
between the different types of journals 
[RR=25, (1.8, 346.7), p-value=0.013, 
Fisher’s exact test]. This suggests that 
RCTs published in C journals are 25 
times more likely to achieve 65% 
CONSORT compliance score than RCTs 
published in NC journals. 
Details on the frequency distribution of each item of the checklist per C / NC journal 
is presented at Table 1. 34 items (47.2%) were reported by more of the 75% of the articles 
in C group whereas the corresponding number for NC is 23 (31.9%), indicating an 
increased tendency, though not statistically significant (P-Value=0.061, Pearson’s Chi 
Square), in the former.  
The number of items per section that are reported by 75% and more of all the 
RCTs and of the studies in C and NC groups separately are presented in Table 2. No 
significant differences (Fisher’s Exact Test, Pearson’s Chi Square) were found between 
C and NC group, regarding any section.   
Mean compliance score for ‘Dental’ and ‘General Scientific’ journals was 
65±6.37% and 46.6±9.58% respectively. The mean difference was 18.4% (95% CI 5.89, 
30.91%), (Independent samples T-Test) and it was statistically significant (P-Value=0.007 
< 0.05). No statistically significant differences in average CONSORT Compliance scores 
were found between the articles published each year (One-Way ANOVA, F=0,065, P-
Value= 0.98 > 0.05) and also between different continents: Europe (48.67%), South 
America (66.4%) and Asia (51.71%), (One-Way ANOVA, F=2.21, P-Value = 0.145 > 
0.05).  
The items that were statistically significant more likely to be reported in C RCTs 
than in NC are the following (Table 3): 
 Items Nr 1 from Tittle (Identification of the trial as ‘randomized’ in the title), Nr 22-24 from 
Introduction (RR=1.2, P-Value<0.001 for each of them) and from Discussion, the items Nr 
64: Trial limitations, 65: Comparison with other findings, 67: Implications, 68: 
Generalizability and 69: Interpretation.  
 Items from Abstract, particularly: Nr 2: structured summary, Nr 4: trial design, Nr 9: clear 
definition of the primary outcome, Nr17: estimated effect size and precision, Nr 12: blinding 
of the care givers and outcome assessors (Nr 13), Nr 20:  registration number and Nr 21: 
source of funding.  
Table 2. Numbers and percentages of CONSORT 
items (overall and by section) reported by 75% or 
more of all the articles or by C / NC journal. 
Journal/Checklist 
items 
TOTAL 
(18 
RCTs)  
N (%) 
CONSORT 
(7 RCTs)  
N (%) 
NO 
CONSORT 
(11 RCTs)  
N (%) 
Overall (72) 26(36.1) 34 (47.2) 23 (31.9) 
Title/Abstract (21) 4(19) 5(23.8) 4(19) 
Introduction (3) 3(100) 3(100) 3(100) 
Materials and 
Methods (24) 
11(45.8) 13(54.2) 11(45.8 ) 
Results (15) 7 (46.7) 9(60) 4(26.7) 
Discussion (6) 0(0) 3(50) 0(0) 
Other Info (3) 1(33.3) 1(33.3) 1(33.3) 
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 Criteria related to randomization -apart from Nr 37 ‘Type of Randomization’-, allocation 
concealment or blinding –except for Nr 45 ‘Description of the similarity of interventions’: 
RRs are the following: Nr 36: 7.21, P-Value<0.001, Nr 38: 24.75 P-Value<0.001, Nr 39: 
6.62 P-Value<0.001, Nr 40: RR=3.44, P-Value<0.001, Nr 41 RR=76.6, P-Value<0.001, Nr 
42 RR=2.04, P-Value=0.02, Nr 43 RR=1.82 P-Value<0.001, Nr 44 RR=2.87, P-
Value<0.001). 
 Item Nr 47: details on ITT analysis 
 Items Nr 49: flow diagram , numbers of participants randomized (Nr 50), received 
treatment (Nr 51), analyzed (Nr 52), lost or excluded (Nr 53) – together with reasons, (Nr 
54)- and all important harms (Nr 63) 
 Trial number registration (Nr 70) and source of funding (Nr 72). 
There were items statistically significant more likely to be reported in NC journals, 
such as: 
 In Abstract: ‘Contact details of the corresponding author’ (Nr 3) and ‘Numbers of 
participants randomized (Nr 14) or analyzed (Nr 15) in each group’. 
 A table with baseline characteristics of the participants (Nr 56) and  
 Results of any other analysis –subgroup and adjusted (Nr 62). 
 
 
Table 3: Percentages of C-NC journals reporting each item and p-values of their RRs by using Pearson’s 
Chi-Square Test or Fisher’s Exact Test 
Nr Modified CONSORT item 
Compliance Compliance  
CONSORT No CONSORT  
N (%) N (%) P-Value 
1 Identification as a randomized trial in the title 7 (100) 4 (36.4) <0.001 
2 Structured summary of trial design, methods, results and 
conclusions  
6 (85.7) 6 (54.5) <0.001 
3 Contact details of the corresponding author 3 (42.9) 11 (100) <0.001 
4 Description or trial design 7 (100) 7 (63.6) <0.001 
5 Eligibility criteria for participants 0 (0) 0 (0) - 
6 Settings where the data were collected 0 (0) 1 (9.1) 0.002 
7 Interventions intended for each group 7 (100) 11 (100) - 
8 Specific objectives or hypotheses for this report 7 (100) 10 (90.9) 0.002 
9 Clearly defined primary outcome for this report 3 (42.9) 1 (9.1) <0.001 
10 How participants were allocated to interventions 1 (14.3) 1 (9.1) 0.27 
11 Whether participants were blinded to group assignment 1 (14.3) 1 (9.1) 0.27 
12 Care givers were blinded to group assignment 1 (14.3) 0 (0) <0.001 
13 Those assessing the outcomes were blinded to group 
assignment 
2 (28.6) 0 (0) <0.001 
14 Number of participants randomized to each group 5 (71.4) 10 (90.9) <0.001 
15 Number of participants analyzed in each group 1 (14.3) 3 (27.3) 0.02 
16  For the primary outcome a result for each group 1 (14.3) 1 (9.1) 0.27 
17 The estimated effect size and its precision 2 (28.6) 1 (9.1) 0.01 
18 Important adverse events or side effects 0 (0) 0 (0) - 
19 General interpretation of the results 5 (71.4) 7 (63.6) 0.29 
20 Registration number and name of trial registry 2 (28.6) 0 (0) <0.001 
21 Source of funding 5 (71.4) 0 (0) <0.001 
22 Scientific background  7 (100) 9 (81.8) <0.001 
23 Explanation of rationale 7 (100) 9 (81.8) <0.001 
24 Specific objectives or hypotheses 7 (100) 9 (81.8) <0.001 
25 Description of trial design (such as parallel, factorial) 6 (85.7) 9 (81.8) 0.44 
26 Allocation ratio 4 (57.1) 9 (81.8) <0.001 
27 Eligibility criteria for participants 7 (100) 11 (100) - 
28 Settings where the data were collected 6 (85.7) 10 (90.9) 0.27 
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29 Locations where the data were collected 6 (85.7) 9 (81.8) 0.44 
30 The interventions for each group with sufficient details to allow 
replication 
7 (100) 10 (90.9) 0.002 
31 How and when they were actually administered 7 (100) 9 (81.8) <0.001 
32 Completely defined pre-specified primary and secondary 
outcome measures 
6 (85.7) 8 (72.7) 0.02 
33 
How primary and secondary outcome measures were assessed 7 (100) 10 (90.9) 0.002 
34 
When primary and secondary outcome measures were assessed 7 (100) 11 (100) - 
35 How sample size was determined 7 (100) 11 (100) - 
36 Method used to generate the random allocation sequence 6 (85.7) 5 (45.5) <0.001 
37 Type of randomization; Details of any restriction (such as blocking and 
block size) 
4 (57.1) 5 (45.5) 0.12 
38 Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers) 
5 (71.4) 1 (9.1) <0.001 
39 Description of any steps taken to conceal the sequence until 
interventions were assigned 
5 (71.4) 3 (27.3) <0.001 
40 Who generated the random allocation sequence  3 (42.9) 2 (18.2) <0.001 
41 Who enrolled participants 3 (42.9) 0 (0) <0.001 
42 Who assigned participants to interventions 3 (42.9) 3 (27.3) 0.018 
43 If done, who was blinded after assignment to interventions (for 
example, participants, care providers, those assessing 
outcomes) 
7 (100) 6 (54.5) <0.001 
44 How was blinding done 5 (71.4) 5 (45.5) <0.001 
45 If relevant, description of the similarity of interventions 2 (28.6) 2 (18.2) 0.13 
46 Statistical methods used to compare groups for primary and 
secondary outcomes 
7 (100) 10 (90.9) 0.002 
47 ITT analysis 3 (42.9) 0 (0) <0.001 
48 Methods for additional analyses, such as subgroup analyses 
and adjusted analyses 
1 (14.3) 2 (18.2) 0.44 
49 Flow diagram 7 (100) 3 (27.3) <0.001 
50 For each group, the numbers of participants who were randomly 
assigned 
7 (100) 9 (81.8) <0.001 
51 For each group, the numbers of participants who received 
intended treatment 
7 (100) 8 (72.7) <0.001 
52 For each group, the numbers of participants who were analyzed 
for the primary outcome 
7 (100) 8 (72.7) <0.001 
53 
For each group, losses and exclusions after randomization 7 (100) 9 (81.8) <0.001 
54 Reasons for losses and exclusions after randomization 5 (100) 4 (80) <0.001 
55 Dates defining the periods of recruitment and follow-up 6 (85.7) 6 (54.5) <0.001 
56 A table showing baseline demographic and clinical 
characteristics for each group 
4 (57.1) 8 (72.7) 0.27 
57 For each group, number of participants (denominator) included 
in each analysis and whether the analysis was by original 
assigned groups 
6 (85.7) 8 (72.7) 0.02 
58 For each primary and secondary outcome, results for each 
group 
7 (100) 10 (90.9) 0.002 
59 For each primary and secondary outcome the estimated effect 
size  
1 (14.3) 1 (9.1) 0.27 
60 For each primary and secondary outcome, its precision (such as 
95% confidence interval) 
0 (0) 0 (0) - 
61 For binary outcomes, presentation of both absolute and relative 
effect sizes is recommended 
0 (0) 0 (0) - 
62 Results of any other analyses performed, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified 
from exploratory 
2 (28.6) 6 (54.5) <0.001 
63 All important harms or unintended effects in each group (for 
specific guidance see CONSORT for harms) 
5 (71.4) 6 (54.5) 0.02 
64 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
6 (85.7) 5 (45.5) <0.001 
65 
Comparison with relevant findings from other published studies 6 (85.7) 6 (54.5) <0.001 
66 Consideration of possible mechanisms and explanation 4 (57.1) 5 (45.5) 0.12 
67 Clinical and research implications 4 (57.1) 4 (36.4) 0.003 
68 Generalizability (external validity, applicability) of the trial 
findings 
4 (57.1) 1 (9.1) <0.001 
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69 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence 
7 (100) 4 (36.4) <0.001 
70 Registration number and name of trial registry 5 (71.4) 1 (9.1) <0.001 
71 Where the full trial protocol can be accessed, if available 4 (57.1) 7 (63.6) 0.31 
72 Sources of funding and other support (such as supply of drugs), 
role of funders 
7 (100) 10 (90.9) 0.002 
 
 
Conclusions 
 
According to the present study the reporting quality of the RCTs for photodynamic 
or laser diode therapy in periodontitis during the period 1.1.2013-30.6.2018 is suboptimal. 
Only 26 of the 72 (36.1%) items from the modified CONSORT 2010 checklist have been 
reported in 75% and more of the RCTs. The poor Compliance Scores could be attributed 
to the high percentage of NO CONSORT articles (64%, 11/18) in the sample. Articles in 
CONSORT endorsing journals include more items from the modified CONSORT list than 
studies in NO CONSORT journals (47.2% and 31.9% of the total items reported by the 
75% or more of the C and NC RCTs, respectively). The majority of relevant RCTs is found 
in General scientific journals (55.6% -10/18) and their reporting quality is significantly 
lower than those’ published in ‘Dental’ journals (CCS: 46.6±9.58% compared to 
65±6.37%, P-Value=0.007). Unfortunately no improvement in the reporting quality of the 
RCTs for PDT / LR in periodontitis has taken place during the last 5 years.  
The highest percentage of items reported by 75% and more of the studies is in 
Introduction by far whereas the lowest is in Discussion. To the low Discussion Compliance 
score contributed the fact that items from Discussion received a negative response in 
case of implementation of improper statistical methods (which applied for the 33.3% of 
the studies). Special concern needs to be raised for the content of Title-Abstract. Although 
this section is essential for reaching a clinical decision or for further selecting of a RCT by 
readers with no full-text access, its reporting quality is dissatisfactory: Only 19% (4/21) of 
its items are reported by 75% or more of the articles. This result corresponds to the finding 
of Lu Jin et al (2016), according to which only 3 out of 16 original Abstract CONSORT 
items (18.8%) were reported in more than 80% of the RCTs originating from four leading 
laser medicine journals during the period 2014-2015. 
Randomization process is also inadequately presented, although most of its items 
are more likely to be reported in C articles than in NC. It is an accepted fact that proper 
randomization involving generation of an unpredictable allocation sequence and 
concealment of this sequence from the investigators enrolling participants (Herman et al, 
2009), is fundamental for the reduction of selection bias at trial entry (Altman, 1991). On 
the other hand blinding prevents from bias arising from assessing subjective outcomes 
(Wood et al, 2008). Consequently, poor reporting of the above elements might indicate 
compromised quality of a RCT. 
In 61.1% (11/18) of the studies, there is no evidence that statistical analysis has 
been implemented regarding the patient as the statistical unit, which is recommended as 
proper, in the case of periodontitis therapy.  
The present study has its weak points. Due to the restricted amount of included 
trials there are limitations in statistical analysis. However, statistically significant 
differences between pre-specified groups have been found. Moreover, RCT evaluation 
was undertaken by a sole scientist venturing the objectiveness of the findings. This 
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constraint has been partially encountered by splitting complex items from the original 
CONSORT 2010 list into simple ones, creating the modified CONSORT item checklist. 
Optimally, inclusion of additional studies covering a longer period of time as well as article 
review by two authors would abrogate the above mentioned limitations.  
Summarizing: 
 The reporting quality of RCTs for PDT or LR therapy in periodontitis during the period 
1.1.2013-30.6.2018 is suboptimal.  
 The majority of the C articles achieve better CCS than NC. 
 The same applies for RCTs in ‘Dental’ journals compared to RCTs published in ‘General 
Scientific’ journals.  
 CONSORT compliance has not changed during the last 5 years. 
 Journal endorsement of the CONSORT statement may enhance the completeness of 
reporting of RCTs and thus provide the clinicians a reliable tool for proper decision making 
and the investigators the capacity to advance clinical research on the particular era. 
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APPENDIX 
 
AUTHOR JOURNAL YEAR  SCORE(%) 
Mastrangelo et al Journal of biological regulators and homeostatic agents 2018  27 
Andrande et al Lasers in Med Science 2017  61 
Segarra-Vidal et al Journal of Clinical Periodontology 2017  69 
Theodoro et al Journal of Photochemistry & Photobiology 2017  68 
Monzavi et al Photodiagnosis and Photodynamic Therapy 2016  54 
Alzoman et al International Journal of Dental Hygiene 2016  47 
Sanz-Sanchez et al Journal of Periodontology 2015  72 
Carvalho et al Journal of Clinical Periodontology 2015  77 
Petalin et al Lasers in Med Science 2015  37 
Qadri et al  Lasers in Med Science 2015  27 
Arweiler et al Journal of Clinical Oral Investigation 2014  60 
Betsy et al Journal of Clinical Periodontology 2014  68 
Saglam et al Lasers in Med Science 2014  57 
Luchesi et al Journal of Clinical Periodontology 2013  58 
Al Askar et al Journal of Photodiagnosis and Photodynamic therapy 2017  29 
Kocak et al Lasers in Med Science 2016  59 
Ramos et al Journal of Clinical Periodontology 2016  68 
Balasubramaniam et al Quintessence 2014  48 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
04/06/2020 22:07:11 EEST - 137.108.70.13
17 
 
BIBLIOGRAPHY 
 
Al-Namankany Abeer A., Paul Ashley, David R. Moles & Susan Parekh, Assessment of the quality of 
reporting of randomized clinical trials in paediatric dentistry journals, Int J Paediatr Dent 2009 19: 318–324. 
Altman DG. Randomization. BMJ 1991; 302:1481-2. 
Annals of Internal Medicine. Information for authors. Available at www.annals.org (accessed 15 Jan 2008). 
Begg, C., Cho, M., Eastwood, S., Horton, R., Moher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz, K. F. & 
Simel, D. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. 
Journal of the American Medical Association (1996), 276, 637–639. 
Bolton S. Independence and statistical inference in clinical trial designs: a tutorial review. J Clin Pharmacol 
1998; 38:408-12 
Cairo F, Sanz I, Matesanz P, Nieri M and Pagliaro U. Quality of reporting of randomized clinical trials in 
implant dentistry. A systematic review on critical aspects in design, outcome assessment and clinical 
relevance. J Clin Periodontol 2012; 39(Suppl. 12): 81–107. 
Cioffi Iacopo and Mauro Farella Quality of randomized controlled trials in dentistry, International Dental 
Journal 2011; 61: 37–42 
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of 
research designs. N Engl J Med. 2000; 342: 1887–92.  
Der Simonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J 
Med 1982; 306:1332-7. 
Egger M, Jüni P, Bartlett C. Value of flow diagrams 51 in reports of randomized controlled trials. JAMA 
2001; 285:1996-9. 
Fleming PS, Buckley N, Seehra J, Polychronopoulou A, Pandis N. Reporting quality of abstracts of 
randomized controlled trials published in leading orthodontic journals from 2006 to 2011. Am J Orthod 
Dentofac Orthop. 2012; 142:451–8.  
Greenland S. Principles of multilevel modelling. Int J Epidemiol 2000; 29:158-67. 
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias 
in randomized trials. BMJ. 2011; 343:d5928. 
Herman A, Botser IB, Tenenbaum S, Chechick A. Intention-to-treat analysis and accounting for missing 
data in orthopaedic randomized clinical trials. J Bone Joint Surg Am 2009; 91: 2137-43. 
Himmeralb Health Sciences Library (The George Washington University), Study Design 101: Randomized 
Controlled Trial, 2011. 
Hopewell Sally, Mike Clarke, David Moher, Elizabeth Wager, Philippa Middleton, Douglas G Altman, 
Kenneth F Schulz and the CONSORT Group. CONSORT for Reporting Randomized Controlled Trials in 
Journal and Conference Abstracts: Explanation and Elaboration, PLOS 2008; January 22 
Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomized trials in 2000 
and 2006: comparative study of articles indexed in PubMed. BMJ 2010; 340:c723 
Kleijnen J, Gøtzsche PC, Kunz R, Oxman AD, Chalmers I. So what’s so special about randomization? In: 
Maynard A, Chalmers I, eds. Non-random reflections on health services research. BMJ Books, 1997:93- 
106. 
Kloukos D., N. Papageorgiou, I Doulis, H. Petridis & N. Pandis: Reporting quality of randomized 
controlled trials published in prosthodontic and implantology journals. Journal of Oral Rehabilitation 2015 
42; 914–925. 
Koletsi Despina, Loukia M. Spineli, Evangelia Lempesi and Nikolaos Pandis: Risk of bias and magnitude 
of effect in orthodontic randomized controlled trials: a meta-epidemiological review, European Journal of 
Orthodontics, 2016, 308–312.  
Lempesi Evangelia, Despina Koletsi, Padhraig S. Fleming and Nikolaos Pandis: The Reporting Quality of 
Randomized Controlled Trials in Orthodontics. J Evid Base Dent Pract 2014; 14: 46-52 
Leow NM, Hussain Z, Petrie A, Donos N, Needleman IG. Has the quality of reporting in periodontology 
changed in 14 years? A systematic review. J Clin Periodontol 2016; 43: 833–838. 
Lucena C, Souza EM, Voinea GC, Pulgar R, Valderrama MJ, De-Deus G. A quality assessment of 
randomized controlled trial reports in endodontics. International Endodontic Journal, 2017, 50, 237–250. 
Lu Jin & Fang Hua & Qiang Cao:  Reporting quality of randomized controlled trial abstracts published in 
leading laser medicine journals: an assessment using the CONSORT for abstracts guidelines, Lasers 
Med Sci 2016 31:1583–1590. 
Institutional Repository - Library & Information Centre - University of Thessaly
04/06/2020 22:07:11 EEST - 137.108.70.13
18 
 
David Moher, Sally Hopewell, Kenneth F Schulz, Victor Montori, Peter C Gøtzsche, P J Devereaux, Diana 
Elbourne, Matthias Egger, Douglas G Altman. CONSORT 2010 Explanation and Elaboration: updated 
guidelines for reporting parallel group randomized trials BMJ 2010; 340: c869 
Moher D, Schulz KF, Altman DG, Lepage L: The CONSORT statement: revised recommendations for 
improving the quality of reports of parallel-group randomized trials. Lancet 2001, 357: 1191–1194. 
Pandis Nikolaos, Argy Polychronopoulou, Theodore Eliades: An assessment of quality characteristics of 
randomized control trials published in dental journals, journal of dentistry. 2010; 38: 713 –721 
Pandis Nikolaos, Larissa Shamseer, Vincent G. Kokicha, Padhraig S. Fleminga, David Moher: Active 
implementation strategy of CONSORT adherence by a dental specialty journal improved randomized 
clinical trial reporting, Journal of Clinical Epidemiology. 2014; 67:1044-1048 
Patel Devangkumar Rajnikant, Tim O’Brien, Aviva Petrie & Haralampos Petridis, Systematic Review of 
Outcome Measurements and Quality of Studies Evaluating Fixed Tooth-Supported Restorations. Journal 
of Prosthodontics. 2014; 23:421–433 
Pandis Nikolaos, Bryan Chung, Roberta W Scherer, Diana Elbourne, Douglas G Altman: CONSORT 
2010 statement: extension checklist for reporting within person randomized trials BMJ 2017; 357: j2835 
Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve 
the quality of reports of randomized controlled trials? A systematic review. Med J Aust 2006; 185:263-7 
Ravindranath Tiruvoipati, Sabapathy P. Balasubramanian, Gnaneswar Atturu, Giles J. Peek and Diana 
Elbourne: Improving the quality of reporting randomized controlled trials in cardiothoracic surgery: The 
way forward, J Thorac Cardiovasc Surg. 2006; 132: 233–240. 
S. Rajasekharan, J. Vandenbulcke, L. Martens: An assessment of the quality of reporting randomized 
controlled trials published in paediatric dentistry journals, Eur Arch Paediatr Dent, 2014, 28 October (on 
line) 
Rios P. Lorena, Adefowope Odueyungbo, Misha O. Moitri, Mohammed O. Rahman and Lehana Thabane: 
Quality of Reporting of Randomized Controlled Trials in General Endocrinology Literature: J Clin 
Endocrinol Metab, October 2008, 93(10):3810–3816 
Saltaji Humam, Susan Armijo-Olivo, Greta G. Cummings, Maryam Amin, Carlos Flores-Mir: Randomized 
clinical trials in dentistry: Risks of bias, risks of random errors, reporting quality and methodologic quality 
over the years 1955±2013, PLOS ONE; 2017, December 22  
Schulz, K. F., Altman, D. G. & Moher, D.: CONSORT 2010 statement: updated guidelines for reporting 
parallel group randomized trials. BMC Medicine. 2010, 8, 1. 
Tonetti M, Palmer R, on behalf of Working Group 2 of the VIII European Workshop on Periodontology: 
Clinical research in implant dentistry: study design, reporting and outcome measurements: consensus 
report of Working Group 2 of the VIII European Workshop on Periodontology. J Clin Periodontol 2012; 39 
(Suppl.12): 73–80. 
Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the 
completeness of reporting of randomized controlled trials (RCTs) published in medical journals. Cochrane 
Database Syst Rev. 2012; 11: MR000030. 
Williams HC. Cars, CONSORT 2010, and clinical practice. Trials. 2010; 11:33. 
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment 
effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. 
BMJ 2008; 336: 601-5. 
http://www.consort-statement.org/ 
http://www.consort-statement.org/about-consort/impact-of-consort 
http://www.consort-statement.org/about-consort/endorsers1 
 
 
  
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
04/06/2020 22:07:11 EEST - 137.108.70.13
19 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
04/06/2020 22:07:11 EEST - 137.108.70.13
